{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Disorders+of+the+Immune+System&page=2", "query": { "condition": "Disorders of the Immune System", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Disorders+of+the+Immune+System&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-26T12:11:23.578Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07513181", "title": "Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ulcerative Colitis", "Inflammatory Bowel Diseases", "Autoimmune Diseases" ], "interventions": [ { "name": "ATH-063", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Athos Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 120, "start_date": "2026-06", "completion_date": "2028-12-14", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-06-26T12:11:23.578Z", "location_count": 2, "location_summary": "Miami, Florida • Roswell, Georgia", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Roswell", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07513181" }, { "nct_id": "NCT05090371", "title": "A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Relapsing-Remitting Multiple Sclerosis" ], "interventions": [ { "name": "Ofatumumab", "type": "DRUG" }, { "name": "Disease modifying treatment (DMT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 136, "start_date": "2022-03-02", "completion_date": "2027-04-13", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-06-26T12:11:23.578Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Cullman, Alabama • Chandler, Arizona + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05090371" }, { "nct_id": "NCT03170271", "title": "A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Benralizumab (Medi-563)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 660, "start_date": "2017-07-07", "completion_date": "2020-10-21", "has_results": true, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-06-26T12:11:23.578Z", "location_count": 100, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 87 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03170271" }, { "nct_id": "NCT00225173", "title": "Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Disease" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Bleomycin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 45, "start_date": "2001-10", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2014-08-27", "last_synced_at": "2026-06-26T12:11:23.578Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00225173" }, { "nct_id": "NCT02770170", "title": "Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lupus Nephritis" ], "interventions": [ { "name": "BI 655064 dose 1", "type": "DRUG" }, { "name": "BI 655064 dose 2", "type": "DRUG" }, { "name": "BI 655064 dose 3", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 121, "start_date": "2016-05-16", "completion_date": "2020-08-18", "has_results": true, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-06-26T12:11:23.578Z", "location_count": 9, "location_summary": "Los Angeles, California • Doral, Florida • Kissimmee, Florida + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Doral", "state": "Florida" }, { "city": "Kissimmee", "state": "Florida" }, { "city": "Plantation", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02770170" }, { "nct_id": "NCT02230969", "title": "Plegridy Observational Program", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Relapsing Forms of Multiple Sclerosis" ], "interventions": [ { "name": "peginterferon beta-1a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1208, "start_date": "2014-11-12", "completion_date": "2022-01-20", "has_results": false, "last_update_posted_date": "2022-09-26", "last_synced_at": "2026-06-26T12:11:23.578Z", "location_count": 50, "location_summary": "Homewood, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 44 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "California City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02230969" }, { "nct_id": "NCT01097369", "title": "Elitek (Rasburicase) Immuno-Monitoring Study", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Tumor Lysis Syndrome" ], "interventions": [], "intervention_types": [], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 1, "start_date": "2010-02", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2013-01-31", "last_synced_at": "2026-06-26T12:11:23.578Z", "location_count": 4, "location_summary": "Valhalla, New York • Oklahoma City, Oklahoma • Memphis, Tennessee + 1 more", "locations": [ { "city": "Valhalla", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01097369" }, { "nct_id": "NCT06539169", "title": "FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Alpha-Thalassemia", "Beta-Thalassemia", "Amyloidosis", "Amyotrophic Lateral Sclerosis", "Creutzfeld-Jakob Disease", "Cystic Fibrosis", "Duchenne Muscular Dystrophy", "Early-Onset Alzheimer Disease", "Ehlers-Danlos Syndrome", "Huntington Disease", "Gaucher Disease", "GM1 Gangliosidosis", "Myasthenia Gravis", "Pompe Disease", "Sickle Cell Disease", "Transthyretin Amyloid Cardiomyopathy", "Rare Diseases" ], "interventions": [], "intervention_types": [], "sponsor": "xCures", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1000, "start_date": "2024-06-10", "completion_date": "2026-06-10", "has_results": false, "last_update_posted_date": "2024-11-14", "last_synced_at": "2026-06-26T12:11:23.578Z", "location_count": 1, "location_summary": "Los Altos, California", "locations": [ { "city": "Los Altos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06539169" }, { "nct_id": "NCT00002105", "title": "Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sarcoma, Kaposi", "HIV Infections" ], "interventions": [ { "name": "Doxorubicin hydrochloride (liposomal)", "type": "DRUG" }, { "name": "Bleomycin sulfate", "type": "DRUG" }, { "name": "Vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sequus Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-06-26T12:11:23.578Z", "location_count": 4, "location_summary": "Boston, Massachusetts • New York, New York • Houston, Texas + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002105" }, { "nct_id": "NCT03454451", "title": "CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Renal Cell Cancer", "Colorectal Cancer", "Triple Negative Breast Cancer", "Cervical Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Endometrial Cancer", "Sarcoma", "Squamous Cell Carcinoma of the Head and Neck", "Bladder Cancer", "Metastatic Castration Resistant Prostate Cancer", "Non-hodgkin Lymphoma" ], "interventions": [ { "name": "CPI-006", "type": "DRUG" }, { "name": "CPI-006 + ciforadenant", "type": "DRUG" }, { "name": "CPI-006 + pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corvus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2018-04-25", "completion_date": "2023-02-19", "has_results": false, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-06-26T12:11:23.578Z", "location_count": 22, "location_summary": "Tucson, Arizona • Duarte, California • San Francisco, California + 18 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03454451" } ] }